Veracyte, Inc. (VCYT) Financial Statements
Industry: Medical Laboratories (Services)
In fiscal 2025, Veracyte reported revenue of $517.1M, up 16.0% from $445.8M the year before. Net income was $66.4M (a 12.8% net margin), or $0.82 per diluted share. Gross margin was 70.1% and operating margin was 11.2%. Operating activities generated $136.3M of cash, leaving $126.6M of free cash flow. At fiscal year end, Veracyte held $1.41B in total assets against $96.4M in total liabilities, including $362.6M of cash and equivalents.
Open the full interactive Veracyte financials → Quarterly statements, key ratios, valuation history and price charts.
Veracyte Key Stats
| Share Price | $43.11 |
|---|---|
| Market Cap | $3.54B |
| P/E Ratio | 52.6 |
| Revenue YoY Growth | +16.0% |
| 52-Week Range | $30.01 – $60.49 |
| Shares Outstanding | 80.0 million (basic, 2026 Q2) |
Veracyte Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $117.5M | $219.5M | $296.5M | $361.1M | $445.8M | $517.1M |
| Cost of Goods Sold | $152.9M | $301.4M | $337.6M | $446.8M | $282.0M | $304.8M |
| Gross Profit | -$35.4M | -$81.9M | -$41.1M | -$85.8M | $298.1M | $362.5M |
| Operating Income | -$35.4M | -$81.9M | -$41.1M | -$85.8M | $16.1M | $57.8M |
| Pre-Tax Income | -$34.8M | -$81.6M | -$36.4M | -$76.6M | $25.7M | $68.2M |
| Income Tax | $0 | -$6.1M | $133,000 | -$2.2M | $1.6M | $1.8M |
| Net Income | -$34.9M | -$75.6M | -$36.6M | -$74.4M | $24.1M | $66.4M |
| Diluted EPS | -$0.66 | -$1.11 | -$0.51 | -$1.02 | $0.31 | $0.82 |
Veracyte Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $131.9M | $140.6M | $139.1M | $150.3M |
| Net Income | $19.1M | $41.1M | $28.7M | $25.5M |
| Diluted EPS | $0.24 | $0.51 | $0.35 | $0.31 |
Veracyte Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $349.4M | $173.2M | $154.2M | $216.5M | $239.1M | $362.6M |
| Current Assets | $375.7M | $243.1M | $248.6M | $285.6M | $372.3M | $488.4M |
| Total Assets | $457.2M | $1.19B | $1.16B | $1.11B | $1.30B | $1.41B |
| Current Liabilities | $16.8M | $64.2M | $62.6M | $61.2M | $78.6M | $59.9M |
| Total Long-Term Debt | $810,000 | $1.1M | — | — | — | — |
| Total Liabilities | $35.9M | $91.3M | $81.2M | $70.8M | $124.1M | $96.4M |
| Shareholders' Equity | $421.2M | $1.10B | $1.08B | $1.04B | $1.18B | $1.31B |
Veracyte Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$9.7M | -$31.6M | $7.5M | $44.2M | $75.1M | $136.3M |
| Cash From Investing | -$3.8M | -$739.2M | -$29.4M | $15.1M | -$56.3M | -$9.2M |
| Cash From Financing | $203.6M | $596.3M | $3.5M | $2.8M | $4.9M | -$4.2M |
| Free Cash Flow | -$12.5M | -$37.0M | -$1.0M | $34.3M | $63.8M | $126.6M |
Figures from Veracyte's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Veracyte financials page for every line item.
Veracyte Company Profile
| Ticker | VCYT |
|---|---|
| Exchange | Nasdaq |
| Industry | Medical Laboratories (Services) |
| Headquarters | South San Francisco, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001384101 |
Frequently Asked Questions
What was Veracyte's revenue in fiscal 2025?
Veracyte (VCYT) reported revenue of $517.1M for fiscal 2025.
What is Veracyte's annual revenue history?
Veracyte's annual revenue by fiscal year: 2020: $117.5M; 2021: $219.5M; 2022: $296.5M; 2023: $361.1M; 2024: $445.8M; 2025: $517.1M.
What was Veracyte's net income in fiscal 2025?
Veracyte reported net income of $66.4M for fiscal 2025.
What was Veracyte's earnings per share (EPS) in fiscal 2025?
Veracyte's diluted EPS was $0.82 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Veracyte generate in fiscal 2025?
Veracyte generated $126.6M of free cash flow in fiscal 2025.
What was Veracyte's revenue last quarter?
In its most recent reported quarter (2026 Q2), Veracyte reported revenue of $150.3M.
How many shares of Veracyte are outstanding?
Veracyte reported a weighted average of 80.0 million basic shares outstanding in 2026 Q2.
What is Veracyte's market cap?
Based on its latest closing price, Veracyte (VCYT) has a market capitalization of about $3.54B.
When does Veracyte's fiscal year end?
Veracyte's fiscal year end, as registered with the SEC, is December 31.
Where is Veracyte headquartered?
Veracyte lists its business address in South San Francisco, California in its SEC filings.